How large pharma impacts biotechnology startup success – Nature Biotechnology
BGV's Daniela Couto and Gina Melcher von Dydiowa together with Sander van Deventer of Forbion published an article in Nature Biotechnology on pharma involvement in biotech startup success. Click on this link to read the whole article. Abstract: Many novel therapeutic...
Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman
Philippe Dro brings entrepreneurial expertise and biotech, medtech and pharma industry experience Successful serial entrepreneur with track record of growing companies, notably for Themis and Glycovaxyn Joins at a key juncture in Scenic Biotech’s strategic growth,...
CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer
Munich, Germany, January 28, 2021 — CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry...
VarmX appoints Dr. Gerard Short as Chief Medical Officer
Leiden, The Netherlands, 27 January 2021 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO). As CMO, Dr. Short...
Positive Phase 2b ICONA interim results for icosabutate in NASH patients
Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients treated for 16 weeksOnce-daily oral icosabutate showed dose-dependent,...
BioGeneration Ventures BGV IV fund closes at €140 million
BGV now one of the largest biotech investors in early stage ventures and company creation in Europe BGV IV includes new investors Eli Lilly and Company and Novo Holdings, joining existing investors Bristol Myers Squibb, European Investment Fund, Industriens Pension,...
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology Bilthoven and Maastricht, The Netherlands, 6 January 2021 – Intravacc, one of the leading translational research and...
Lonza, Forbion and BioGeneration Ventures Announce Collaboration for Development and Manufacture of Biologics for Portfolio Companies
The four-year agreement provides benefits for portfolio companies of Forbion and BioGeneration Ventures (BGV) Lonza to provide de-risking, development and manufacturing services for large molecule biologics The agreement will streamline the gene to IND process,...
FIRST completes its investment in TargED for the development of Microlyse – a next-generation thrombolytic clot-busting drug
November 24th, 2020, Utrecht, the Netherlands TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht founded by Associate prof. Coen Maas, PhD, Steven de Maat, PhD, Marc van Moorsel and Kristof Vercruysse, raised EUR 1.35 million to...
NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline
• NST becomes a multi-asset clinical development company, beyond NASH• Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control• A third clinical development...